Nonalcoholic Steatohepatitis NASH - Biotech, Pharma and Life Science Channel
Nonalcoholic steatohepatitis or NASH is a common, often “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly.
NASH affects 2 to 5 percent of Americans. An additional 10 to 20 percent of Americans have fat in their liver, but no inflammation or liver damage, a condition called “fatty liver.” Although having fat in the liver is not normal, by itself it probably causes little harm or permanent damage. If fat is suspected based on blood test results or scans of the liver, this problem is called nonalcoholic fatty liver disease (NAFLD). If a liver biopsy is performed in this case, it will show that some people have NASH while others have simple fatty liver.
Both NASH and NAFLD are becoming more common, possibly because of the greater number of Americans with obesity. In the past 10 years, the rate of obesity has doubled in adults and tripled in children. Obesity also contributes to diabetes and high blood cholesterol, which can further complicate the health of someone with NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.
Source: NDDIC
PubMed Articles
Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
Non-alcoholic fatty liver disease (NAFLD) is now recognised as the hepatic component of metabolic syndrome (MetS). NAFLD is an example of ectopic fat accumulation in a visceral organ that causes organ...
Genetic aspects of migraine headaches.
Physical activity for the prevention and treatment of metabolic disorders.
Metabolic syndrome and its various features (obesity, hypertension, dyslipidemia, diabetes, and nonalcoholic fatty liver disease) are increasing worldwide and constitute a severe risk for the sustaina...
Context.-The incidence of obesity is increasing and contributes to the rising incidence of fatty liver. Body mass index (BMI) is used to assess the degree of obesity but does not take into account the...
Fetuin-A mRNA expression is elevated in NASH compared to NAFL patients.
Background: Fetuin-A is a pro-inflammatory protein expressed by hepatocytes. Its course in morbidly obese patients with NAFLD following weight loss by bariatric surgery (BAS) has not been fully elucid...
BACKGROUND AND AIM: Metabolic syndrome (MS) is likely to be associated with nonalcoholic fatty liver disease (NAFLD). The prevalence of NAFLD in visceral fat type MS (V-type MS) is known to be higher...
The growing incidence of obesity is a worldwide public health problem leading to a risk factor for non-alcoholic fatty liver disease, which extends from steatosis to steatohepatitis and cirrhosis. We...
INTRODUCTION: Decompression with fusion is usually recommended in patients with lumbar spinal stenosis (LSS) combined with degenerative lumbar scoliosis (DLS). However, elderly patients with LSS and D...
Hydrological models have been increasingly used by hydrologists and water resource managers to understand natural processes and human activities that affect watersheds. In this study, we use the physi...
BACKGROUND: Some research evidence from Western populations suggests that lower vitamin D is associated with the prevalence and histologically assessed severity of nonalcoholic fatty liver disease (NA...
News Articles
Hemoglobin May Be Toxic for the Diseased Liver
A new study suggests that high levels of hemoglobin may be dangerous in patients with nonalcoholic fatty liver disease,...
Galectin Therapeutics Reports First Quarter 2013 Financial Results
NORCROSS, Ga., May 10, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today repo...
Why Aren’t More People Filling Their Prescriptions?
Ellen Nash, 20, a college sophomore, had been taking a generic asthma drug for a year, with a copay of just $5, when her doctor decided to switch her to a newer drug. He wanted to put Nash on the diff...
Analyst Downgrades Ironwood Pharma on Expenses
A Cowen & Co. analyst downgraded shares of Ironwood Pharmaceuticals Inc. Monday, citing the company's growing expenses and disappointing early sales of its bowel drug Linzess. THE OPINION: Analyst...
Zohydro - Is There Enough Upside For Zogenix?
By Alpha Cardinal: By Jordan Plews, Ph.D.; T. Bacaj, Ph.D.; and Paul Nash, Ph.D. Zogenix is a pharmaceutical company specializing in the commercialization and development of products for the treatme...
Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies
NORCROSS, Ga., April 29, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today released dat...
Vitamin D Therapy Could Be A Powerful Weapon In The Fight Against Liver Fibrosis
Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury lea...
Study demonstrates accuracy of non-invasive test for NASH diagnosis
A Chinese study presented at the International Liver CongressTM 2013 has demonstrated the accuracy of a non-invasive test for non-alcoholic steatohepatitis (NASH) diagnosis.
Calcipotriol drug offers a potential treatment option for fibrotic diseases
Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury lea...
Nonalcoholic Fatty Liver Disease Prevented By Dietary Medium Chain Triglycerides
Scientists at the Arkansas Children's Nutrition Center, a U.S. Department of Agriculture Agricultural Research Service Human Nutrition Research Center at the University of Arkansas for Medical Science...
Events
None
Companies
Tivorsan Pharmaceuticals http://www.tivorsan.com is a protein therapeutics company pioneering a unique approach to treating serious neuromuscular disorders, including DMD and Beck...
Founded in 1962, M+NLB is a full-service mechanical, electrical, plumbing, and technology engineering consulting and design firm, also providing value-added commissioning, equipme...
Tivorsan Pharmaceuticals, Inc.
Tivorsan Pharmaceuticals, Inc. is a protein therapeutics company pioneering a unique approach to treating serious neuromuscular disorders, including DMD and Becker Muscular...
Clinical Trials
This is a prospective, multi-center, randomized, placebo-controlled trial in subjects with histological evidence of > 33% hepatic steatosis or nonalcoholic steatohepatitis (NASH) and chron...
Insulin resistance (IR), a key factor in the development of steatosis, is a common finding in patients with hepatitis C virus (HCV) infection. In patients with genotype 1 infection, IR has...
This study aims to evaluate the impact of nasal continuous positive airway pressure (nCPAP) treatment on liver enzymes in patients with sleep apnea syndrome and nonalcoholic steatohepatiti...
Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type...
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol. The etiology of NASH is unclear, but...
Effects of a Low Glycemic Load Diet on Fatty Liver in Children
There has been a recent increase in incidence of obesity and its associated morbidities, including T2 DM, hypertension and hepatic steatosis. Hepatic steatosis is a precursor to non-alcoh...
Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome
Non-alcoholic fatty liver disease (NAFLD) is now recognised as the hepatic complication of the metabolic syndrome of insulin resistance. In some patients, the disease can progress into ste...
The histological characteristics of alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH) related to overweight and obesity suggest the presence of partly common physiopat...
Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver dis...
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underly...
Videos
Nonalcoholic Steatohepatitis (NASH) - Dr. Julie Heimbach
Dr. Julie Heimbach, Surgical Director of the Liver Transplant Program in Rochester, MN, gives an overview of Nonalcoholic Steatohepatitis (NASH).
